Patients with advanced non-clear cell renal cell carcinoma have a high prevalence of germline mutations, including some that could be used to guide therapy.
The finding suggests that, in the setting of a CD117-positive renal tumor biopsy, this modality could reduce patient morbidity and health care costs by avoiding the need for resection in benign cases.
Costs could be slashed by $320 million if all men with Gleason scores of 6 or lower pursued initial conservative management, says researcher Justin Trogdon, PhD.
In women with mixed urinary incontinence, a combined conservative and surgical treatment approach provided significant improvements versus surgical treatment alone.
“I think this study indicates that this is a procedure that not only improves detection, but also has a high rate of perceived value for patients, and therefore would be worthwhile to use in practice,” says researcher Angela B. Smith, MD.
High levels of visceral fat were associated with a significantly increased risk of death in women with clear cell renal cell carcinoma, but not in men, results of a recent retrospective study show.
“The findings should serve as a call to action for urologic specialists who care for patients with cancer,” says Alexander Kutikov, MD.
Biopsy decreases overall uncertainty, is safe, fairly accurate, relatively inexpensive, and improves shared decision-making with patients.
Renal mass biopsy provides actionable information, but only under specific circumstances—yet it is an increasingly necessary part of the nuanced patient discussion.
Practicing urologists should consider the potential value of performing a multiparametric MRI for a biopsy in men with suspected prostate cancer based on results from the PRECISION trial, says Veeru Kasivisvanathan, MRCS.